文献速递慢性肾脏病肾血管病与高血压

KNOW-CKD研究:收缩压达标时间越长,CKD进展风险越低

Findings from the KNOW-CKD Study indicate that higher systolic blood pressure time in target range is associated with a lower risk of chronic kidney disease progression.
PubMed 文献 · Kidney Int · 2023-12-28

该研究基于KNOW-CKD队列1758例CKD患者,分析入组第一年收缩压达标时间比例(SBP-TTR)与CKD进展的关联。中位随访5.4年间,SBP-TTR每增加1个标准差,复合终点风险降低11%(HR 0.89,95%CI 0.82-0.97)。与SBP-TTR为0%者相比,51-99%和100%组CKD进展风险显著降低。

要点

  • SBP-TTR每升高1个标准差,CKD进展风险降低11%(HR 0.89)。
  • SBP-TTR越高,eGFR下降斜率越平缓。

核心结论

  • 在CKD患者中,较高的收缩压达标时间比例(SBP-TTR)与较低的CKD进展风险独立相关。

研究设计与样本

  • 基于韩国KNOW-CKD前瞻性队列,纳入1758例CKD患者,基线中位eGFR为51.7 ml/min/1.73 m²。
  • 根据入组第一年SBP-TTR分为0%、1-50%、51-99%和100%四组,中位随访5.4年(共9212人年)。

主要发现

  • 随访期间共710例发生复合终点(eGFR较基线下降≥50%或启动肾脏替代治疗)。
  • 多因素病因特异性风险模型中,SBP-TTR每增加1个标准差,复合终点风险降低11%(HR 0.89,95%CI 0.82-0.97)。
  • 与SBP-TTR 0%组相比,51-99%组HR为0.76(95%CI 0.60-0.96),100%组HR为0.72(95%CI 0.55-0.94)。
  • SBP-TTR 0%、1-50%、51-99%和100%组对应的eGFR下降斜率分别为-3.17、-3.02、-2.62和-2.33 ml/min/1.73 m²。

关键数值与推荐

  • SBP-TTR定义为收缩压处于预设最佳范围内的时间比例。
  • CKD进展定义为eGFR较基线下降≥50%或启动肾脏替代治疗。

临床怎么用

  • 临床可将SBP-TTR作为评估CKD患者长期血压控制质量的指标。
  • 提高SBP达标时间比例可能有助于延缓CKD进展。

局限性

  • 原文摘要未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Time-in-target range (TTR) of systolic blood pressure (SBP) is determined by the proportion of time during which SBP remains within a defined optimal range. TTR has emerged as a useful metric for assessing SBP control over time. However, it is uncertain if SBP-TTR can predict the progression of chronic kidney disease (CKD). Here, we investigated the association between SBP-TTR during the first year of enrollment and CKD progression among 1758 participants from the KNOW-CKD (KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease). Baseline median estimated glomerular filtration rate (eGFR) was 51.7 ml/min per 1.73 m2. Participants were categorized into four SBP-TTR groups (0%, 1-50%, 51-99%, and 100%). The primary outcome was CKD progression defined as 50% or more decline in eGFR from baseline measurement or the initiation of kidney replacement therapy. During the follow-up period (9212 person-years over a median 5.4 years), the composite outcome occurred in 710 participants. In the multivariate cause-specific hazard model, a one-standard deviation increase in SBP-TTR was associated with an 11% lower risk of the composite outcome with hazard ratio, 0.89 (95% confidence interval, 0.82-0.97). Additionally, compared to patients with SBP-TTR 0%, the respective hazard ratios for those with SBP-TTR 1-50%, 51-99%, and 100% were 0.85 (0.68-1.07), 0.76 (0.60-0.96), and 0.72 (0.55-0.94), and the respective corresponding slopes of eGFR decline were -3.17 (-3.66 to -2.69), -3.02 (-3.35 to -2.68), -2.62 (-2.89 to - 2.36), and -2.33 (-2.62 to -2.04) ml/min/1.73 m2. Thus, higher SBP-TTR was associated with a decreased risk of CKD progression in patients with CKD.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Park CH, Kim HW, Joo YS, et al. Findings from the KNOW-CKD Study indicate that higher systolic blood pressure time in target range is associated with a lower risk of chronic kidney disease progression. Kidney Int. 2023. PMID: 38159679. doi:10.1016/j.kint.2023.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。